Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Giovanni Paniccia"'
Autor:
Antonella Tripiciano, Orietta Picconi, Sonia Moretti, Cecilia Sgadari, Aurelio Cafaro, Vittorio Francavilla, Angela Arancio, Giovanni Paniccia, Massimo Campagna, Maria Rosaria Pavone-Cossut, Laura Sighinolfi, Alessandra Latini, Vito S. Mercurio, Massimo Di Pietro, Francesco Castelli, Annalisa Saracino, Cristina Mussini, Giovanni Di Perri, Massimo Galli, Silvia Nozza, Fabrizio Ensoli, Paolo Monini, Barbara Ensoli
Publikováno v:
EBioMedicine, Vol 66, Iss , Pp 103306- (2021)
Background: Low-level HIV viremia originating from virus reactivation in HIV reservoirs is often present in cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery of CD4+ T cells. The HI
Externí odkaz:
https://doaj.org/article/347c39a646b64210952c288b56fdfe12
Autor:
Cecilia Sgadari, Paolo Monini, Antonella Tripiciano, Orietta Picconi, Anna Casabianca, Chiara Orlandi, Sonia Moretti, Vittorio Francavilla, Angela Arancio, Giovanni Paniccia, Massimo Campagna, Stefania Bellino, Marianna Meschiari, Silvia Nozza, Laura Sighinolfi, Alessandra Latini, Antonio Muscatello, Annalisa Saracino, Massimo Di Pietro, Massimo Galli, Aurelio Cafaro, Mauro Magnani, Fabrizio Ensoli, Barbara Ensoli
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Introduction: Tat, a key HIV virulence protein, has been targeted for the development of a therapeutic vaccine aimed at cART intensification. Results from phase II clinical trials in Italy (ISS T-002) and South Africa (ISS T-003) indicated that Tat v
Externí odkaz:
https://doaj.org/article/c78e740c80274a2887513b75affaebd7
Autor:
Barbara Ensoli, Stefania Bellino, Antonella Tripiciano, Olimpia Longo, Vittorio Francavilla, Simone Marcotullio, Aurelio Cafaro, Orietta Picconi, Giovanni Paniccia, Arianna Scoglio, Angela Arancio, Cristina Ariola, Maria J Ruiz Alvarez, Massimo Campagna, Donato Scaramuzzi, Cristina Iori, Roberto Esposito, Cristina Mussini, Florio Ghinelli, Laura Sighinolfi, Guido Palamara, Alessandra Latini, Gioacchino Angarano, Nicoletta Ladisa, Fabrizio Soscia, Vito S Mercurio, Adriano Lazzarin, Giuseppe Tambussi, Raffaele Visintini, Francesco Mazzotta, Massimo Di Pietro, Massimo Galli, Stefano Rusconi, Giampiero Carosi, Carlo Torti, Giovanni Di Perri, Stefano Bonora, Fabrizio Ensoli, Enrico Garaci
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13540 (2010)
UnlabelledAlthough HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservo
Externí odkaz:
https://doaj.org/article/6ed34be1303c4aca8283aa4593dab48a
Autor:
Giovanni Di Perri, Giovanni Paniccia, Cecilia Sgadari, Barbara Ensoli, Laura Sighinolfi, Sonia Moretti, Paolo Monini, Annalisa Saracino, Maria Rosaria Pavone-Cossut, Vito S. Mercurio, Massimo Di Pietro, Alessandra Latini, Orietta Picconi, Francesco Castelli, Fabrizio Ensoli, Angela Arancio, Vittorio Francavilla, Silvia Nozza, Aurelio Cafaro, Massimo Galli, Massimo Campagna, Antonella Tripiciano, Cristina Mussini
Publikováno v:
EBioMedicine, Vol 66, Iss, Pp 103306-(2021)
Background Low-level HIV viremia originating from virus reactivation in HIV reservoirs is often present in cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery of CD4+ T cells. The HIV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1f46c63d116b2bc081ae5af416a2de
http://hdl.handle.net/11379/561565
http://hdl.handle.net/11379/561565
Autor:
Stefania Bellino, Mauro Magnani, Fabrizio Ensoli, Alessandra Latini, Marianna Meschiari, Annalisa Saracino, Chiara Orlandi, Vittorio Francavilla, Barbara Ensoli, Angela Arancio, Aurelio Cafaro, Giovanni Paniccia, Laura Sighinolfi, Silvia Nozza, Massimo Di Pietro, Orietta Picconi, Massimo Galli, Anna Casabianca, Antonio Muscatello, Sonia Moretti, Cecilia Sgadari, Massimo Campagna, Antonella Tripiciano, Paolo Monini
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology
Frontiers in Immunology
Introduction: Tat, a key HIV virulence protein, has been targeted for the development of a therapeutic vaccine aimed at cART intensification. Results from phase II clinical trials in Italy (ISS T-002) and South Africa (ISS T-003) indicated that Tat v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0ad66d3e50b928131aa3a607ce1d7e
https://hdl.handle.net/11380/1258955
https://hdl.handle.net/11380/1258955
Autor:
Mauro Magnani, Fabrizio Ensoli, Paolo Monini, Vittorio Francavilla, Maria Rosaria Pavone Cossut, Angela Arancio, Giovanni Paniccia, Anna Casabianca, John Velaphi Ndimande, Aurelio Cafaro, Orietta Picconi, Stefano Buttò, Yogan Pillay, Olimpia Longo, Stefania Bellino, Bennett Asia, Antonella Tripiciano, Barbara Ensoli, Lara Tavoschi, Cecilia Sgadari, Sonia Moretti, Barbara Collacchi, Daniel Joffe, Maphoshane Nchabeleng, Enrico Garaci, Elise Levendal
Publikováno v:
Retrovirology
Background Although combined antiretroviral therapy (cART) has saved millions of lives, it is incapable of full immune reconstitution and virus eradication. The transactivator of transcription (Tat) protein is a key human immunodeficiency virus (HIV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9086b56844a3f1b27990a43e3a0f7865
https://doi.org/10.1186/s12977-016-0261-1
https://doi.org/10.1186/s12977-016-0261-1
Autor:
Guido Palamara, Alessandra Latini, Giuseppe Tambussi, Paolo Monini, Adriano Lazzarin, Barbara Ensoli, Gianpiero D'Offizi, Maria Josè Ruiz Alvarez, Enrico Garaci, Barbara Collacchi, Massimo Giuliani, Arianna Scoglio, Aldo Di Carlo, Chiara Tassan Din, Marina Giulianelli, Maria Carta, Andrea Antinori, Pasquale Narciso, Stefania Bellino, Antonella Tripiciano, Olimpia Longo, Mauro Magnani, Fabrizio Ensoli, Valeria Fiorelli, Vittorio Francavilla, Angela Arancio, Giovanni Paniccia, Raffaele Visintini
Publikováno v:
Vaccine. 28:371-378
The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials based on its role in the natural infection and AIDS pathogenesis, on the association of Tat-specific immune response with the asymptomatic stage as well as on it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ab576d949def5c4965dadc95265cd0
https://doi.org/10.1016/j.vaccine.2009.10.038
https://doi.org/10.1016/j.vaccine.2009.10.038
Autor:
Vittorio Francavilla, Olimpia Longo, Adriano Lazzarin, A. Di Carlo, Mauro Magnani, Antonella Tripiciano, Guido Palamara, Fabrizio Ensoli, Angela Arancio, Giuseppe Tambussi, Marinella Giulianelli, Gianpiero D’Offizi, Paolo Monini, C. Tassan Din, Arianna Scoglio, Maria Carta, Giovanni Paniccia, Raffaele Visintini, Pasquale Narciso, Maria Elena Laguardia, Massimo Giuliani, Stefania Bellino, Andrea Antinori, Massimo Campagna, Barbara Ensoli, Valeria Fiorelli, Barbara Collacchi
Publikováno v:
ResearcherID
The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials in both uninfected (ClinicalTrials.gov identifier: NCT00529698) and infected volunteers (ClinicalTrials.gov identifier: NCT00505401). The rationale was based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a00dc39673b678e7f54c606b3d7c12f
https://doi.org/10.2174/157488709789957529
https://doi.org/10.2174/157488709789957529
Autor:
Laura Sighinolfi, Guido Palamara, Massimo Di Pietro, Barbara Ensoli, Angela Arancio, Sonia Moretti, Mauro Magnani, Stefania Bellino, Fabrizio Ensoli, Vito S. Mercurio, Francesco Castelli, Leonardo Sernicola, Enrico Garaci, Maria Teresa Maggiorella, Andrea Gori, Giovanni Di Perri, Cecilia Sgadari, Massimo Galli, Vittorio Francavilla, Orietta Picconi, Anna Casabianca, Olimpia Longo, Chiara Orlandi, Aurelio Cafaro, Adriano Lazzarin, Antonella Tripiciano, Cristina Mussini, Maria Rosaria Pavone Cossut, Giovanni Paniccia, Gioacchino Angarano, Paolo Monini
Publikováno v:
Retrovirology
Background The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a2cf6d52134d2c173aba40b3865e00
https://doi.org/10.1186/s12977-015-0151-y
https://doi.org/10.1186/s12977-015-0151-y
Autor:
Giuseppe Tambussi, Paolo Monini, Giovanni Paniccia, Guido Palamara, Angela Arancio, Emanuele Focà, Alessandra Latini, Massimo Di Pietro, Vito S. Mercurio, Fabrizio Ensoli, Laura Sighinolfi, Giovanni Di Perri, Antonella Tripiciano, Stefania Bellino, Orietta Picconi, Cecilia Sgadari, Andrea Gori, Cristina Mussini, Olimpia Longo, Stefano Bonora, Gioacchino Angarano, Nicoletta Ladisa, Vittorio Francavilla, Massimo Galli, Silvia Nozza, Francesco Mazzotta, Barbara Ensoli, Aurelio Cafaro, Adriano Lazzarin, Carlo Torti
Publikováno v:
Retrovirology
Background: Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on both the virus and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22a012fc75080a3e99541001d491e74
https://doi.org/10.1186/1742-4690-11-49
https://doi.org/10.1186/1742-4690-11-49